Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) announced the appointment of John Palma as vice president of Medical Affairs. With over 26 years in diagnostics and research, Palma will lead the companywide Global Medical Affairs organization, focusing on liquid biopsy development. His prior experience includes senior roles at Roche, enhancing Agilent's position in cancer diagnostics and precision oncology. This strategic move follows Agilent's acquisition of Resolution Bioscience, demonstrating a commitment to advancing capabilities in next-generation sequencing.
Agilent Technologies (NYSE: A) has launched the new 6560C Ion Mobility LC/Q-TOF, enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges. These innovations support biopharma research, enhancing the analysis of proteins and peptides, crucial for developing new therapeutics. They address regulatory compliance and improve data integrity. Agilent's solutions are showcased at the American Society for Mass Spectrometry Conference from October 31 to November 4, 2021, in Philadelphia.
Agilent Technologies (NYSE: A) announced that its PD-L1 IHC 22C3 pharmDx assay is now approved for identifying triple-negative breast cancer (TNBC) patients eligible for treatment with KEYTRUDA® in Europe. PD-L1 expression is crucial for anti-PD-1 therapy responses. The assay, already used in four other cancer types, enhances pathologists' ability to identify suitable patients. With over 530,000 new breast cancer cases in Europe in 2020, this approval significantly expands Agilent's diagnostic capabilities, reinforcing its leadership in companion diagnostics.
Agilent Technologies Inc. (NYSE: A) will announce its fourth-quarter fiscal year 2021 financial results post market close on November 22, 2021. A live webcast of the investor conference call will take place at 1:30 p.m. Pacific Time on the same day. In fiscal year 2020, the company reported a revenue of $5.34 billion and employs 16,400 people globally. The webcast will be available on their website for 90 days after the event.
Summary not available.
Agilent Technologies (NYSE: A) has achieved the highest sponsorship level with My Green Lab as the first to do so. This partnership enhances Agilent's commitment to sustainability in scientific research, emphasizing green purchasing practices. Since its inception in 2013, My Green Lab focuses on improving environmental responsibility in labs. Agilent has received My Green Lab's ACT labels for major product lines and sponsors the certification program recognized in the UNFCCC's 2030 Breakthroughs. Agilent is consistently ranked among the world's most sustainable corporations.
Agilent Technologies Inc. (NYSE: A) has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx, intended to assist in first-line treatment decisions for adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric and esophageal cancers are significant global health issues, with over 1.6 million cases reported in 2020. The PD-L1 IHC 28-8 pharmDx enhances treatment confidence when used with OPDIVO® (nivolumab), demonstrating superior survival rates compared to chemotherapy alone.
Agilent Technologies (NYSE: A) announced FDA approval for its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) as a diagnostic tool for early breast cancer (EBC) patients at high risk of disease recurrence. This assay, developed in partnership with Eli Lilly, is the first to be approved for use with the drug Verzenio (abemaciclib). The approval is critical for better recurrence risk assessment, complementing traditional staging methods. This move positions Agilent as a key player in the diagnostic assay market, enhancing treatment decision-making for high-risk EBC patients.
Agilent Technologies (NYSE: A) awarded the Agilent Thought Leader Award to Professor Bernhard Lendl from TU Wien for his pioneering work in vibrational spectroscopy. This award aims to enhance infrared quantum cascade laser applications in biopharma, specifically improving analysis methods for biomolecules in challenging aqueous environments. The recognition highlights the importance of advancing analytical tools for rapid assessment of therapeutic proteins and viral vectors, addressing critical bottlenecks in biopharmaceutical workflows.
Agilent Technologies, Inc. (NYSE: A) has appointed Dr. Mikael Dolsten, Pfizer's Chief Scientific Officer, to its board of directors effective September 21, 2021. Dr. Dolsten brings over 30 years of pharmaceutical expertise, having led numerous drug candidates into human studies and contributing to the development of over 30 approved drugs and vaccines. His leadership in small-molecule medicines and biotherapeutics is expected to enhance Agilent's strategic initiatives. This appointment is seen as a significant addition to the board, aiming to strengthen Agilent's capabilities in life sciences and diagnostics.